VAMP7 Antibody

What is VAMP7 and why is it important in cellular research?

VAMP7 (Vesicle-associated membrane protein 7) is a 25 kDa type IV transmembrane protein belonging to the synaptobrevin family. Mature human VAMP7 consists of a 187 amino acid cytoplasmic domain, a 21 amino acid transmembrane region, and an 11 amino acid vesicular region . The cytoplasmic domain contains a longin domain (aa 7-110) and a v-SNARE coiled-coil homology domain (aa 125-185) .

VAMP7 is crucial in multiple cellular processes:

• Membrane fusion events mediating neurite outgrowth in developing neurons

• Endosome to lysosome transport

• Lysosomal secretion at immune synapses

• Autophagy-related processes

• Exocytosis during phagocytosis

Human VAMP7 shares 99%, 97%, and 95% amino acid sequence identity with bovine, mouse, and rat VAMP7, respectively , making it highly conserved across species.

What are the different applications of VAMP7 antibodies?

VAMP7 antibodies have been validated for multiple research applications:

Research shows that careful selection of fixation and permeabilization methods significantly affects detection quality in immunofluorescence applications .

How do monoclonal and polyclonal VAMP7 antibodies differ in research applications?

Both monoclonal and polyclonal antibodies have specific advantages in VAMP7 research:

Monoclonal antibodies:

• Provide consistent lot-to-lot reproducibility

• Offer higher specificity for particular epitopes

• Example: Mouse monoclonal clone 158.2 (reacting with AA 119-188) shows excellent specificity in knockout validation studies

• Particularly valuable for quantitative studies requiring reproducible results

Polyclonal antibodies:

• Recognize multiple epitopes, potentially increasing detection sensitivity

• May detect different isoforms of VAMP7

• Example: Rabbit polyclonal antibodies targeting N-terminal regions can detect the two longest isoforms of VAMP7

• Useful when protein conformation or post-translational modifications might mask epitopes

A comparative study by Verraes et al. using CRISPR/Cas9 VAMP7 knockout cells demonstrated variability in antibody performance, highlighting the importance of validation .

How can I validate VAMP7 antibody specificity for my research?

Rigorous validation of VAMP7 antibodies is essential for reliable results. The following methodological approach is recommended:

• CRISPR/Cas9 knockout controls:

  • Generate VAMP7 knockout cells using CRISPR/Cas9 technology as negative controls

  • Compare antibody reactivity between wild-type and knockout samples

• Multiple detection methods:

  • Cross-validate using different techniques (WB, IF, IP)

  • Compare staining patterns with published VAMP7 localization data (late endosomes, lysosomes)

• Specificity profiling:

  • Western blot analysis should show a predominant band at 25 kDa

  • Calculate specificity index using: (intensity of VAMP7 band)/(total lane intensity)

  • Evaluate background staining in knockout samples

• Isoform distinction:

  • Determine which VAMP7 isoforms your antibody detects

  • At least three isoforms of VAMP7 exist; some antibodies detect only specific isoforms

A comprehensive study by Verraes et al. (2019) demonstrated that visual scoring of immunocytochemistry combined with western blot profiling provides robust validation .

What are the optimal conditions for VAMP7 detection by Western blotting?

Successful Western blot detection of VAMP7 requires optimized protocols:

Sample preparation:

• Use RIPA or NP-40 based lysis buffers with protease inhibitors

• Include reducing agents, though higher molecular weight bands (47 kDa, 150 kDa) may persist despite strong reducing conditions

• For complete de-aggregation of VAMP7, consider urea-containing solubilization buffers

Gel and transfer conditions:

• 12-15% SDS-PAGE gels provide optimal separation

• PVDF membranes are recommended for VAMP7 detection

• Transfer in 25 mM Tris, 192 mM glycine, 20% methanol

Detection optimization:

• Use Immunoblot Buffer Group 1 for optimal results with some antibodies

• Block with 5% non-fat milk or BSA in TBST

• Primary antibody incubation: overnight at 4°C (1:800-1:8000 dilution)

• HRP-conjugated secondary antibodies provide reliable detection

Expected results: A specific band at approximately 25 kDa, with possible detection of multimeric forms at 47 kDa and 150 kDa in some tissue preparations .

How do I optimize immunofluorescence protocols for VAMP7 subcellular localization studies?

Accurate visualization of VAMP7's subcellular distribution requires careful methodology:

Fixation and permeabilization:

• 4% paraformaldehyde (10-15 minutes) followed by 0.1-0.2% Triton X-100 or 0.1% saponin

• Avoid methanol fixation as it can disrupt membrane protein epitopes

• For co-localization studies, ensure compatibility with other target proteins

Blocking and antibody incubation:

• Block with 5-10% normal serum from secondary antibody species

• Primary antibody dilutions typically range from 1:50-1:500

• Secondary antibody selection should minimize cross-reactivity

Co-localization markers:

• LAMP1 for lysosomal localization

• PDI for endoplasmic reticulum localization

• LC3 for autophagosome association

Analysis approaches:

• Line tracing analysis can quantify co-localization patterns

• Z-stack imaging is essential for accurate co-localization assessment

• Visual scoring criteria should include evaluation of Golgi-like and peripheral vesicular patterns versus incorrect perinuclear or diffuse signals

Example study: Chen et al. used VAMP7 antibodies to study colocalization with ANXA2, GFP-LC3, and LAMP1 in cells treated with IFN-gamma, revealing VAMP7's role in autophagy-mediated exosomal secretion .

How can VAMP7 antibodies be used in immunoprecipitation to study SNARE complex interactions?

Immunoprecipitation (IP) of VAMP7 requires specialized protocols to preserve protein-protein interactions:

Optimized IP protocol:

• Lysis buffer selection:

  • Use mild detergents (0.5-1% NP-40 or 1% digitonin)

  • Include 150 mM NaCl, 50 mM Tris-HCl pH 7.4, and protease inhibitors

  • Add phosphatase inhibitors if studying phosphorylation-dependent interactions

• Pre-clearing step:

  • Incubate lysate with protein A/G beads (1 hour, 4°C)

  • Remove beads to reduce non-specific binding

• Antibody binding:

  • Use 0.5-4.0 μg antibody per 1-3 mg protein lysate

  • Incubate overnight at 4°C with gentle rotation

  • Add protein A/G beads for additional 2-4 hours

• Washing and elution:

  • Perform 4-5 washes with decreasing salt concentration

  • Elute with SDS sample buffer (70°C, 10 minutes)

• Analysis:

  • Detect VAMP7 and interacting proteins by Western blot

  • Use knockout samples as essential negative controls

This methodology has been validated in studies exploring VAMP7's interactions with other SNARE proteins in various complexes, including syntaxin 4-SNAP 23-VAMP7 and syntaxin 7-syntaxin 8-Vti1b-VAMP7 .

What experimental approaches can distinguish between different VAMP7 isoforms?

Differentiating between VAMP7 isoforms requires specialized methodological approaches:

Isoform characteristics:

• Isoform 1: Full-length VAMP7 (standard form)

• Isoform 2: Contains a 116 aa substitution for aa 145-220 found in isoform 1

• Isoform 3: Missing residues corresponding to aa 28-68 in isoform 1

Experimental differentiation methods:

• Antibody selection:

  • Use epitope-specific antibodies targeting unique regions

  • Antibodies against N-terminal regions typically detect the two longest isoforms

  • Confirm specificity using 2D gel electrophoresis followed by Western blot

• RT-PCR analysis:

  • Design primers spanning unique junction regions

  • Use isoform-specific primers for quantitative analysis

• 2D gel electrophoresis:

  • Separate VAMP7 isoforms by isoelectric point and molecular weight

  • Follow with Western blot detection using VAMP7 antibodies

  • Research indicates this approach can distinguish the expected 25 kDa isoform from potential aggregates or multimers

• Mass spectrometry:

  • Perform immunoprecipitation of VAMP7

  • Analyze by MALDI-TOF to identify specific isoforms

  • This approach has confirmed multiple molecular weight bands as true VAMP7 with Z scores of 2.4

Understanding isoform-specific distribution and function remains an active area of research in VAMP7 biology.

How can VAMP7 antibodies be used to study its role in disease models?

VAMP7 has been implicated in various pathological conditions, and antibody-based studies provide crucial insights:

Allergy and inflammation models:

• VAMP7 mediates eosinophil degranulation in allergy-related airway hyperresponsiveness

• Studies with eoCRE/V7 mice (VAMP7 gene deficiency in eosinophils) demonstrate reduced degranulation responses and decreased airway hyperresponsiveness

• Methodology: Combine intratracheal adoptive transfer of eosinophils with ex vivo assessment using VAMP7 antibodies to track degranulation events

Immune synapse function:

• B-cells rely on VAMP7 for local exocytosis of lysosomes at immune synapses

• This process is required for antigen extraction and presentation

• Experimental approach: Use VAMP7 antibodies in conjunction with antigen presentation assays and live cell imaging

Autophagy dysregulation:

• VAMP7 participates in amphisome/lysosome fusion during autophagy

• Knockdown experiments with VAMP7 siRNA followed by antibody detection of autophagy markers can reveal its specific contributions

• Analysis method: Triple colocalization experiments with VAMP7, LC3, and lysosomal markers using confocal microscopy

Experimental considerations:

• Include appropriate controls (siRNA knockdown or CRISPR/Cas9 knockout)

• Validate antibody specificity in the specific tissue/cell type being studied

• Combine functional assays with localization studies for comprehensive understanding

• Consider compensatory mechanisms by other SNARE proteins

These approaches have revealed critical insights into VAMP7's pathophysiological roles across multiple disease models.

What are the most effective strategies for troubleshooting non-specific binding with VAMP7 antibodies?

Even validated VAMP7 antibodies can produce non-specific signals that require systematic troubleshooting:

Western blot troubleshooting:

• High molecular weight bands:

  • Several studies report 47 kDa and 150 kDa bands in addition to the expected 25 kDa band

  • These may represent true multimers resistant to standard reducing agents

  • Solution: Try urea-containing solubilization buffers, which have been shown to de-aggregate VAMP7

• Non-specific banding:

  • Calculate specificity index: (intensity of VAMP7 band)/(total lane intensity)

  • A comparative study found specificity indices ranging from 0.05 to 0.85 across different antibodies

  • Solution: Optimize blocking conditions (5% milk vs. BSA) and increase washing stringency

• Weak signal:

  • Some antibodies show weak reactivity to endogenous VAMP7

  • Solution: Try antibody concentration of 1 μg/mL for optimal detection

Immunofluorescence troubleshooting:

• High background:

  • Visual scoring approach is recommended over simple intensity profiling

  • Evaluate Golgi-like and peripheral vesicular patterns versus incorrect diffuse signals

  • Solution: Pre-adsorb antibody or try longer/more stringent washing steps

• Poor signal-to-noise ratio:

  • Some fixation methods may mask VAMP7 epitopes

  • Solution: Try different fixation protocols or antigen retrieval methods

• Non-specific nuclear staining:

  • This pattern is inconsistent with VAMP7's known localization

  • Solution: Use a validated antibody that shows appropriate vesicular/endosomal patterns

Proper controls, including VAMP7 knockout samples, remain the gold standard for distinguishing specific from non-specific signals in all applications.